Download PDF
Journal of Pediatric Neurology 2015; 13(01): 058-061
DOI: 10.1055/s-0035-1555157
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Management of Pediatric Pseudotumor Cerebri Syndrome

Valeria Dipasquale
1   Department of Pediatrics, University of Messina, Messina, Italy
,
Gabriella Di Rosa
2   Division of Infantile Neuropsychiatry, Department of Pediatrics, University of Messina, Messina, Italy
,
Salvatore Savasta
3   Department of Pediatrics, University of Pavia, IRCCS San Matteo, Pavia, Italy
,
Ornella Merlo
4   Faculty of Medicine and Surgery, University of Messina, Messina, Italy
,
Daniela Concolino
5   Department of Pediatrics, Magna Graecia University, Catanzaro, Italy
,
Teresa Arrigo
1   Department of Pediatrics, University of Messina, Messina, Italy
› Author Affiliations
Further Information

Publication History

17 January 2015

15 February 2015

Publication Date:
13 July 2015 (online)

    Permissions and Reprints

Abstract

Pseudotumor cerebri syndrome (PTCS) is a clinical condition characterized by signs and symptoms of elevated intracranial pressure without any radiographic evidence of a mass lesion in the brain, and no abnormalities of the brain parenchyma and cerebrospinal fluid (CSF) composition. Children with PTCS typically present with various combinations of headache, diplopia, and pulsatile tinnitus. Although this syndrome has long been considered a benign condition, it may lead to permanent visual impairment if not promptly and correctly treated. Complete remission of PTCS is associated with a decrease in intracranial pressure, the disappearance of clinical symptoms, and the reversion of papilledema at the funduscopic examination. PTCS has been associated with several comorbidities, but its exact pathophysiology has yet to be fully elucidated. Because the origin of PTCS remains unclear, an etiologically targeted treatment has not yet been identified. Current medical treatments include diuretics (e.g., acetazolamide, furosemide) able to reduce CSF production and pressure, and CSF diversion procedures in the most severe cases. Future elucidation of the pathophysiologic mechanism(s) underlying impaired CSF dynamics in PTCS should help control more finely the CSF formation by choroid plexus with novel drugs having fewer side effects than the commonly used diuretics (e.g., acetazolamide). In this review, we briefly summarize the current therapeutic options in pediatric PTCS.

Keywords

idiopathic intracranial hypertension - pseudotumor cerebri - management - children
 

  • References

  • 1 Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 2013; 81 (13) 1159-1165
    CrossrefPubMedGoogle Scholar
  • 2 Radhakrishnan K, Ahlskog JE, Cross SA, Kurland LT, O'Fallon WM. Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol 1993; 50 (1) 78-80
    CrossrefPubMedGoogle Scholar
  • 3 Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002; 59 (10) 1492-1495
    CrossrefPubMedGoogle Scholar
  • 4 Salpietro V, Polizzi A, Di Rosa G , et al. Adrenal disorders and the paediatric brain: pathophysiological considerations and clinical implications. Int J Endocrinol 2014; 2014: 282489
    PubMedGoogle Scholar
  • 5 Rangwala LM, Liu GT. Pediatric idiopathic intracranial hypertension. Surv Ophthalmol 2007; 52 (6) 597-617
    CrossrefPubMedGoogle Scholar
  • 6 Salpietro V, Ruggieri M. Pseudotumor cerebri pathophysiology: the likely role of aldosterone. Headache 2014; 54 (7) 1229
    CrossrefPubMedGoogle Scholar
  • 7 Salpietro V, Chimenz R, Arrigo T, Ruggieri M. Pediatric idiopathic intracranial hypertension and extreme childhood obesity: a role for weight gain. J Pediatr 2013; 162 (5) 1084
    PubMedGoogle Scholar
  • 8 Standridge SM. Idiopathic intracranial hypertension in children: a review and algorithm. Pediatr Neurol 2010; 43 (6) 377-390
    CrossrefPubMedGoogle Scholar
  • 9 Paley GL, Sheldon CA, Burrows EK, Chilutti MR, Liu GT, McCormack SE. Overweight and obesity in pediatric secondary pseudotumor cerebri syndrome. Am J Ophthalmol 2015; 159 (2) 344-52.e1
    CrossrefPubMedGoogle Scholar
  • 10 Soiberman U, Stolovitch C, Balcer LJ, Regenbogen M, Constantini S, Kesler A. Idiopathic intracranial hypertension in children: visual outcome and risk of recurrence. Childs Nerv Syst 2011; 27 (11) 1913-1918
    CrossrefPubMedGoogle Scholar
  • 11 Ko MW, Liu GT. Pediatric idiopathic intracranial hypertension (pseudotumor cerebri). Horm Res Paediatr 2010; 74 (6) 381-389
    CrossrefPubMedGoogle Scholar
  • 12 Galgano MA, Deshaies EM. An update on the management of pseudotumor cerebri. Clin Neurol Neurosurg 2013; 115 (3) 252-259
    CrossrefPubMedGoogle Scholar
  • 13 Spennato P, Ruggiero C, Parlato RS , et al. Pseudotumor cerebri. Childs Nerv Syst 2011; 27 (2) 215-235
    CrossrefPubMedGoogle Scholar
  • 14 Salpietro V, Ruggieri M, Sancetta F , et al. New insights on the relationship between pseudotumor cerebri and secondary hyperaldosteronism in children. J Hypertens 2012; 30 (3) 629-630
    PubMedGoogle Scholar
  • 15 Friedman DI, Jacobson DM. Idiopathic intracranial hypertension. J Neuroophthalmol 2004; 24 (2) 138-145
    CrossrefPubMedGoogle Scholar
  • 16 King JO, Mitchell PJ, Thomson KR, Tress BM. Cerebral venography and manometry in idiopathic intracranial hypertension. Neurology 1995; 45 (12) 2224-2228
    CrossrefPubMedGoogle Scholar
  • 17 Mathews MK, Sergott RC, Savino PJ. Pseudotumor cerebri. Curr Opin Ophthalmol 2003; 14 (6) 364-370
    CrossrefPubMedGoogle Scholar
  • 18 Johnson LN, Krohel GB, Madsen RW, March Jr GA. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology 1998; 105 (12) 2313-2317
    CrossrefPubMedGoogle Scholar
  • 19 Liu GT, Volpe NJ, Galetta SL. Pseudotumor cerebri and its medical treatment. Drugs Today (Barc) 1998; 34 (6) 563-574
    CrossrefPubMedGoogle Scholar
  • 20 McCarthy KD, Reed DJ. The effect of acetazolamide and furosemide on cerebrospinal fluid production and choroid plexus carbonic anhydrase activity. J Pharmacol Exp Ther 1974; 189 (1) 194-201
    PubMedGoogle Scholar
  • 21 Kesler A, Hadayer A, Goldhammer Y, Almog Y, Korczyn AD. Idiopathic intracranial hypertension: risk of recurrences. Neurology 2004; 63 (9) 1737-1739
    CrossrefPubMedGoogle Scholar
  • 22 Kahle KT, Walcott BP, Staley KJ. Resolution of headache and papilledema in idiopathic intracranial hypertension associated with inhibition of Na+-K+-2Cl- cotransport. J Child Neurol 2011; 26 (2) 205-208
    CrossrefPubMedGoogle Scholar
  • 23 Celebisoy N, Gökçay F, Sirin H, Akyürekli O. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand 2007; 116 (5) 322-327
    CrossrefPubMedGoogle Scholar
  • 24 Deftereos SN, Panagopoulos G, Georgonikou D, Karageorgiou CE, Karageorgiou E, Piadites G. Treatment of idiopathic intracranial hypertension: is there a place for octreotide?. Cephalalgia 2011; 31 (16) 1679-1680
    CrossrefPubMedGoogle Scholar
  • 25 Salpietro V, Ruggieri M, Alterio T , et al. Is there a risk of pubertal worsening in primary intestinal lymphangiectasia?. J Endocrinol Invest 2013; 36 (11) 1128
    PubMedGoogle Scholar
  • 26 Burness CB, Dhillon S, Keam SJ. Lanreotide Autogel(®): a review of its use in the treatment of patients with acromegaly. Drugs 2014; 74 (14) 1673-1691
    CrossrefPubMedGoogle Scholar
  • 27 Khan MU, Khalid H, Salpietro V, Weber KT. Idiopathic intracranial hypertension associated with either primary or secondary aldosteronism. Am J Med Sci 2013; 346 (3) 194-198
    CrossrefPubMedGoogle Scholar
  • 28 Salpietro V, Mankad K, Kinali M , et al. Pediatric idiopathic intracranial hypertension and the underlying endocrine-metabolic dysfunction: a pilot study. J Pediatr Endocrinol Metab 2014; 27 (1-2) 107-115
    PubMedGoogle Scholar
  • 29 Salpietro V, Polizzi A, Bertè LF , et al. Idiopathic intracranial hypertension: a unifying neuroendocrine hypothesis through the adrenal-brain axis. Neuroendocrinol Lett 2012; 33 (6) 569-573
    PubMedGoogle Scholar
  • 30 Binder DK, Horton JC, Lawton MT, McDermott MW. Idiopathic intracranial hypertension. Neurosurgery 2004; 54 (3) 538-551 , discussion 551–552
    CrossrefPubMedGoogle Scholar
  • 31 Chumas PD, Kulkarni AV, Drake JM, Hoffman HJ, Humphreys RP, Rutka JT. Lumboperitoneal shunting: a retrospective study in the pediatric population. Neurosurgery 1993; 32 (3) 376-383 , discussion 383
    CrossrefPubMedGoogle Scholar
  • 32 Eggenberger ER, Miller NR, Vitale S. Lumboperitoneal shunt for the treatment of pseudotumor cerebri. Neurology 1996; 46 (6) 1524-1530
    CrossrefPubMedGoogle Scholar
  • 33 Thuente DD, Buckley EG. Pediatric optic nerve sheath decompression. Ophthalmology 2005; 112 (4) 724-727
    CrossrefPubMedGoogle Scholar
  • 34 Goh KY, Schatz NJ, Glaser JS. Optic nerve sheath fenestration for pseudotumor cerebri. J Neuroophthalmol 1997; 17 (2) 86-91
    PubMedGoogle Scholar